

Axicabtagene ciloleucel

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Axicabtagene ciloleucel

ATC codes

[L01XL03](#)

Medicine type

Biological agent

EML status history

Application rejected in 2023 ([TRS 1049](#)) for [Diffuse large B-cell lymphomas](#)

Wikipedia

[Axicabtagene ciloleucel](#)

DrugBank

[Axicabtagene ciloleucel](#)

Recommendations

Section

Antineoplastics and supportive medicines

- Cell suspension for infusion:  $2 \times 10^6$  anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

[Diffuse large B-cell lymphomas](#)